Functionality of HDL: Antioxidation and detoxifying effects

Handbook of Experimental Pharmacology

Volumn 224, Issue , 2015, Pages 207-228

  Karlsson, Helen ^a   Kontush, Anatol ^b   James, Richard W ^c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b INSERM   (France)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Antiviral activity; Bacterial pathogen; Bisphenol; HDL; Lipoproteins; Nanoparticles; Organophosphates; Oxidative stress; Paraoxonase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 4,4' ISOPROPYLIDENEDIPHENOL; APOLIPOPROTEIN A1; APOLIPOPROTEIN D; APOLIPOPROTEIN M; ARYLDIALKYLPHOSPHATASE 1; CARBON NANOTUBE; CHOLESTEROL ESTER TRANSFER PROTEIN; CLUSTERIN; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN RECEPTOR; LIPOTEICHOIC ACID; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; METAL OXIDE; MYELOPEROXIDASE; NANOPARTICLE; ORGANOPHOSPHATE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; POLYCHLORINATED BIPHENYL; POLYGLACTIN; SERUM AMYLOID A; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BACTERIAL VIRULENCE; CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CONFERENCE PAPER; CYTOKINE RELEASE; DENGUE; DETOXIFICATION; DIABETES MELLITUS; ENDOCYTOSIS; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; HEPATITIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; HYDROPHILICITY; INNATE IMMUNITY; KIDNEY DYSFUNCTION; LIPID PEROXIDATION; LUNG LAVAGE; METABOLIC SYNDROME X; NANOTECHNOLOGY; NONHUMAN; NOSE MUCUS; OXIDATIVE STRESS; PERSISTENT ORGANIC POLLUTANT; PROTEIN FUNCTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RISK FACTOR; TRYPANOSOMA; TRYPANOSOMA RHODESIENSE; ADVERSE EFFECTS; ANIMAL; BLOOD; ENVIRONMENTAL EXPOSURE; METABOLISM;

ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ENVIRONMENTAL EXPOSURE; HUMANS; LIPOPROTEINS, HDL; OXIDATIVE STRESS;

EID: 84919683044     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-319-09665-0_5     Document Type: Conference Paper

References (118)

1. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN (1995) Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15(11):1812-1818
2. Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2001) Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J Biol Chem 276(27):24473-24481
3. Aldridge WN (1953) Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J 53(1):117-124
4. Androutsopoulos VP, Kanavouras K, Tsatsakis AM (2011) Role of paraoxonase 1 (PON1) in organophosphate metabolism: implications in neurodegenerative diseases. Toxicol Appl Pharmacol 256(3):418-424
5. Artl A, Marsche G, Lestavel S, Sattler W, Malle E (2000) Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 20 (3):763-772
6. Aviram M (2012) Atherosclerosis: cell biology and lipoproteins - paraoxonases protect against atherosclerosis and diabetes development. Curr Opin Lipidol 23(2):169-171
7. Bashtovyy D, Jones MK, Anantharamaiah GM, Segrest JP (2011) Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function. J Lipid Res 52 (3):435-450
8. Besler C, Luscher TF, Landmesser U (2012) Molecular mechanisms of vascular effects of highdensity lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 4(4):251-268
9. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL (2008) Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299(11):1265-1276
10. Birjmohun RS, van Leuven SI, Levels JH, van’t Veer C, Kuivenhoven JA, Meijers JC, Levi M, Kastelein JJ, van der Poll T, Stroes ES (2007) High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 27(5):1153-1158
11. Bisgaier CL, Sachdev OP, Megna L, Glickman RM (1985) Distribution of apolipoprotein A-IV in human plasma. J Lipid Res 26(1):11-25
12. Bowry VW, Stanley KK, Stocker R (1992) High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 89 (21):10316-10320
13. Cabana VG, Lukens JR, Rice KS, Hawkins TJ, Getz GS (1996) HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J Lipid Res 37(12):2662-2674
14. Cabana VG, Gidding SS, Getz GS, Chapman J, Shulman ST (1997) Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 42 (5):651-655
15. Cai L, de Beer MC, de Beer FC, van der Westhuyzen DR (2005) Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem 280(4):2954-2961
16. Chiba T, Chang MY, Wang S, Wight TN, McMillen TS, Oram JF, Vaisar T, Heinecke JW, De Beer FC, De Beer MC, Chait A (2011) Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler Thromb Vasc Biol 31(6):1326-1332
17. Christison JK, Rye KA, Stocker R (1995) Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res 36(9):2017-2026
18. Christison J, Karjalainen A, Brauman J, Bygrave F, Stocker R (1996) Rapid reduction and removal of HDL- but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. Biochem J 314(Pt 3):739-742
19. Costa LG, Giordano G, Cole TB, Marsillach J, Furlong CE (2013) Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology 307:115-122
20. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A (2009) Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 29(6):870-876
21. Du Y, Yang Y, Jiang W, Wang L, Jia XJ, Si SY, Chen XF, Hong B (2012) Substituted benzamides containing azaspiro rings as upregulators of apolipoprotein A-I transcription. Molecules 17
22. Elsoe S, Ahnstrom J, Christoffersen C, Hoofnagle AN, Plomgaard P, Heinecke JW, Binder CJ, Bjorkbacka H, Dahlback B, Nielsen LB (2012) Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis 221(1):91-97
23. Feingold KR, Grunfeld C (2011) The role of HDL in innate immunity. J Lipid Res 52(1):1-3
24. Ferretti G, Bacchetti T, Moroni C, Vignini A, Curatola G (2003) Copperinduced oxidative damage on astrocytes: protective effect exerted by human high density lipoproteins. Biochim Biophys Acta 1635(1):48-54
25. Flo TH, Halaas O, Lien E, Ryan L, Teti G, Golenbock DT, Sundan A, Espevik T (2000) Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol 164(4):2064-2069
26. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R (1998) Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 273(11):6088-6095
27. Gaut JP, Heinecke JW (2001) Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med 11(3-4):103-112. doi:10.1016/S1050-1738(01)00101-3
28. Ghafouri B, Stahlbom B, Tagesson C, Lindahl M (2002) Newly identified proteins in human nasal lavage fluid from non-smokers and smokers using two-dimensional gel electrophoresis and peptide mass fingerprinting. Proteomics 2(1):112-120
29. Ghafouri B, Tagesson C, Lindahl M (2003) Mapping of proteins in human saliva using two-dimensional gel electrophoresis and peptide mass fingerprinting. Proteomics 3 (6):1003-1015
30. Goulinet S, Chapman MJ (1997) Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol 17(4):786-796
31. Goyal J, Wang K, Liu M, Subbaiah PV (1997) Novel function of lecithin-cholesterol acyltransferase. Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation. J Biol Chem 272(26):16231-16239
32. Graner M, James RW, Kahri J, Nieminen MS, Syvanne M, Taskinen MR (2006) Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 47(12):2429-2435
33. Gu JG, Zhu CL, Cheng DZ, Xie Y, Liu F, Zhou X (2011) Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication. Lipids Health Dis 10:154
34. Henning MF, Herlax V, Bakas L (2011) Contribution of the C-terminal end of apolipoprotein AI to neutralization of lipopolysaccharide endotoxic effect. Innate Immun 17(3):327-337
35. Huang Y, Wu Z, Riwanto M, Gao S, Levison BS, Gu X, Fu X, Wagner MA, Besler C, Gerstenecker G, Zhang R, Li XM, DiDonato AJ, Gogonea V, Tang WH, Smith JD, Plow EF, Fox PL, Shih DM, Lusis AJ, Fisher EA, DiDonato JA, Landmesser U, Hazen SL (2013) Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 123(9):3815-3828
36. Huen K, Harley K, Brooks J, Hubbard A, Bradman A, Eskenazi B, Holland N (2009) Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms. Environ Health Perspect 117(10):1632-1638
37. Imrie HJ, Fowkes FJ, Migot-Nabias F, Luty AJ, Deloron P, Hajduk SL, Day KP (2012) Individual variation in levels of haptoglobin-related protein in children from Gabon. PLoS ONE 7(11): e49816
38. James RW (2006) A long and winding road: defining the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 44(9):1052-1059. doi:10.1515/CCLM.2006.207
39. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20:2441-2447
40. Juhas M, Eberl L, Tummler B (2005) Quorum sensing: the power of cooperation in the world of Pseudomonas. Environ Microbiol 7(4):459-471
41. Kaji H (2013) High-density lipoproteins and the immune system. J Lipids 2013:684903
42. Karedal MH, Mortstedt H, Jeppsson MC, Kronholm Diab K, Nielsen J, Jonsson BA, Lindh CH (2010) Time-dependent proteomic iTRAQ analysis of nasal lavage of hairdressers challenged by persulfate. J Proteome Res 9(11):5620-5628
43. Karlsson H, Ljunggren S, Ahrén M, Ghafouri B, Uvdahl K, Lindahl M, Ljungman A (2012) Two-dimensional gel electrophoresis and mass spectrometry in studies of nanoparticle-protein interactions. In: Magdeldin S (ed) Gel glectrophoresis - advanced techniques. In Tech, Rijeka
44. Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS (2013) Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults. Lipids Health Dis 12:23
45. Khersonsky O, Tawfik DS (2005) Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44(16):6371-6382
46. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45(7):1169-1196
47. Kim TH, Lee YH, Kim KH, Lee SH, Cha JY, Shin EK, Jung S, Jang AS, Park SW, Uh ST, Kim YH, Park JS, Sin HG, Youm W, Koh ES, Cho SY, Paik YK, Rhim TY, Park CS (2010) Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med 182(5):633-642
48. Klimov AN, Gurevich VS, Nikiforova AA, Shatilina LV, Kuzmin AA, Plavinsky SL, Teryukova NP (1993) Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis 100 (1):13-18
49. Klimov AN, Kozhevnikova KA, Kuzmin AA, Kuznetsov AS, Belova EV (2001) On the ability of high density lipoproteins to remove phospholipid peroxidation products from erythrocyte membranes. Biochemistry (Mosc) 66(3):300-304
50. Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58(3):342-374
51. Kontush A, Chapman MJ (2010) Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 21(4):312-318
52. Kontush A, Chantepie S, Chapman MJ (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23(10):1881-1888
53. Kontush A, Therond P, Zerrad A, Couturier M, Negre-Salvayre A, de Souza JA, Chantepie S, Chapman MJ (2007) Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 27(8):1843-1849
54. Koren-Gluzer M, Aviram M, Meilin E, Hayek T (2011) The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates beta-cell insulin release. Atherosclerosis 219(2):510-518
55. Kotosai M, Shimada S, Kanda M, Matsuda N, Sekido K, Shimizu Y, Tokumura A, Nakamura T, Murota K, Kawai Y, Terao J (2013) Plasma HDL reduces nonesterified fatty acid hydroperoxides originating from oxidized LDL: a mechanism for its antioxidant ability. Lipids 48(6):569-578
56. Kriska T, Marathe GK, Schmidt JC, McIntyre TM, Girotti AW (2007) Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides. J Biol Chem 282(1):100-108
57. Kumpula LS, Kumpula JM, Taskinen MR, Jauhiainen M, Kaski K, Ala-Korpela M (2008) Reconsideration of hydrophobic lipid distributions in lipoprotein particles. Chem Phys Lipids 155(1):57-62
58. Levels JH, Abraham PR, van Barreveld EP, Meijers JC, van Deventer SJ (2003) Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect Immun 71(6):3280-3284
59. Levels JH, Geurts P, Karlsson H, Maree R, Ljunggren S, Fornander L, Wehenkel L, Lindahl M, Stroes ES, Kuivenhoven JA, Meijers JC (2011) High-density lipoprotein proteome dynamics in human endotoxemia. Proteome Sci 9(1):34
60. Li Y, Kakinami C, Li Q, Yang B, Li H (2013) Human apolipoprotein A-I is associated with dengue virus and enhances virus infection through SR-BI. PLoS ONE 8(7):e70390
61. Lind PM, van Bavel B, Salihovic S, Lind L (2012) Circulating levels of persistent organic pollutants (POPs) and carotid atherosclerosis in the elderly. Environ Health Perspect 120 (1):38-43
62. Ljunggren S, Helmfrid I, Salihovic S, van Bavel B, Wingren G, Lindahl M, Karlsson H (2014) Persistent organic pollutants distribution in lipoprotein fractions in relation to cardiovascular disease and cancer. Environ Int 65:93-99
63. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M (2003) Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107(22):2775-2779
64. Maddipati KR, Marnett LJ (1987) Characterization of the major hydroperoxide-reducing activity of human plasma. Purification and properties of a selenium-dependent glutathione peroxidase. J Biol Chem 262(36):17398-17403
65. Marrache S, Dhar S (2013) Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proc Natl Acad Sci U S A 110(23):9445-9450
66. Massamiri T, Tobias PS, Curtiss LK (1997) Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role of apolipoprotein A-I. J Lipid Res 38(3):516-525
67. McPherson PA, Young IS, McEneny J (2007) A dual role for lecithin:cholesterol acyltransferase (EC 2.3.1.43) in lipoprotein oxidation. Free Radic Biol Med 43(11):1484-1493
68. Miyata M, Smith JD (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14(1):55-61
69. Miyazaki A, Sakai M, Suginohara Y, Hakamata H, Sakamoto Y, Morikawa W, Horiuchi S (1994) Acetylated low density lipoprotein reduces its ligand activity for the scavenger receptor after interaction with reconstituted high density lipoprotein. J Biol Chem 269(7):5264-5269
70. Molina Portela MP, Raper J, Tomlinson S (2000) An investigation into the mechanism of trypanosome lysis by human serum factors. Mol Biochem Parasitol 110(2):273-282
71. Molina-Portela Mdel P, Lugli EB, Recio-Pinto E, Raper J (2005) Trypanosome lytic factor, a subclass of high-density lipoprotein, forms cation-selective pores in membranes. Mol Biochem Parasitol 144(2):218-226
72. Nguyen SD, Jeong TS, Sok DE (2006) Apolipoprotein A-I-mimetic peptides with antioxidant actions. Arch Biochem Biophys 451(1):34-42
73. Nicholas BL, Skipp P, Barton S, Singh D, Bagmane D, Mould R, Angco G, Ward J, Guha- Niyogi B, Wilson S, Howarth P, Davies DE, Rennard S, O’Connor CD, Djukanovic R (2010) Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181(10):1049-1060
74. Nuchi CD, Hernandez P, McClements DJ, Decker EA (2002) Ability of lipid hydroperoxides to partition into surfactant micelles and alter lipid oxidation rates in emulsions. J Agric Food Chem 50(19):5445-5449
75. Ohnsorg PM, Rohrer L, Perisa D, Kateifides A, Chroni A, Kardassis D, Zannis VI, von Eckardstein A (2011) Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells. J Biol Chem 286(10):7744-7754
76. Omiecinski CJ, Vanden Heuvel JP, Perdew GH, Peters JM (2011) Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. Toxicol Sci 120(Suppl 1):S49-S75
77. Ostos MA, Conconi M, Vergnes L, Baroukh N, Ribalta J, Girona J, Caillaud JM, Ochoa A, Zakin MM (2001) Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21(6):1023-1028
78. Ozer EA, Pezzulo A, Shih DM, Chun C, Furlong C, Lusis AJ, Greenberg EP, Zabner J (2005) Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorumsensing. FEMS Microbiol Lett 253(1):29-37
79. Parthasarathy S, Barnett J, Fong LG (1990) High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1044(2):275-283
80. Proudfoot JM, Barden AE, Loke WM, Croft KD, Puddey IB, Mori TA (2009) HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res 50(4):716-722
81. Ramachandran G (2013) Gram-positive and gram-negative bacterial toxins in sepsis: a brief review. Virulence 5(1)
82. Rantamaki AH, Seppanen-Laakso T, Oresic M, Jauhiainen M, Holopainen JM (2011) Human tear fluid lipidome: from composition to function. PLoS ONE 6(5):e19553
83. Ronn M, Lind PM, Karlsson H, Cvek K, Berglund J, Malmberg F, Orberg J, Lind L, Ortiz-Nieto F, Kullberg J (2013) Quantification of total and visceral adipose tissue in fructose-fed rats using water-fat separated single echo MRI. Obesity (Silver Spring) 21(9):E388-E395
84. Rosenblat M, Volkova N, Aviram M (2011) Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity. Biofactors 37(6):462-467
85. Rosenblat M, Elias A, Volkova N, Aviram M (2013) Monocyte-macrophage membrane possesses free radicals scavenging activity: stimulation by polyphenols or by paraoxonase 1 (PON1). Free Radic Res 47(4):257-267
86. Russell JA (2006) Management of sepsis. N Engl J Med 355(16):1699-1713
87. Sempf K, Arrey T, Gelperina S, Schorge T, Meyer B, Karas M, Kreuter J (2013) Adsorption of plasma proteins on uncoated PLGA nanoparticles. Eur J Pharm Biopharm 85(1):53-60
88. Shih DM, Lusis AJ (2009) The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol 20(4):288-292
89. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394(6690):284-287
90. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ (2000) Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275(23):17527-17535
91. Shin JY, Yang Y, Heo P, Lee JC, Kong B, Cho JY, Yoon K, Shin CS, Seo JH, Kim SG, Kweon DH (2013) pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. Int J Nanomed 7:2805-2816
92. Singh IP, Chopra AK, Coppenhaver DH, Ananatharamaiah GM, Baron S (1999) Lipoproteins account for part of the broad non-specific antiviral activity of human serum. Antiviral Res 42 (3):211-218
93. Soran H, Younis NN, Charlton-Menys V, Durrington P (2009) Variation in paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol 20(4):265-274
94. Sparks DL, Davidson WS, Lund-Katz S, Phillips MC (1995) Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J Biol Chem 270 (45):26910-26917
95. Srinivas RV, Birkedal B, Owens RJ, Anantharamaiah GM, Segrest JP, Compans RW (1990) Antiviral effects of apolipoprotein A-I and its synthetic amphipathic peptide analogs. Virology 176(1):48-57
96. Stocker R, Keaney JF Jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84 (4):1381-1478
97. Stoltz DA, Ozer EA, Taft PJ, Barry M, Liu L, Kiss PJ, Moninger TO, Parsek MR, Zabner J (2008) Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1. J Clin Invest 118(9):3123-3131
98. Subbaiah PV, Liu M (1993) Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction. J Biol Chem 268(27):20156-20163
99. Tang WH, Hartiala J, Fan Y, Wu Y, Stewart AF, Erdmann J, Kathiresan S, Roberts R, McPherson R, Allayee H, Hazen SL (2012) Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol 32(11):2803-2812
100. Teeguarden J, Hanson-Drury S, Fisher JW, Doerge DR (2013) Are typical human serum BPA concentrations measurable and sufficient to be estrogenic in the general population? Food Chem Toxicol 62:949-963
101. Teiber JF, Draganov DI, La Du BN (2004) Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J Lipid Res 45 (12):2260-2268
102. Teiber JF, Horke S, Haines DC, Chowdhary PK, Xiao J, Kramer GL, Haley RW, Draganov DI (2008) Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone. Infect Immun 76 (6):2512-2519
103. Troughton JA, Woodside JV, Yarnell JW, Arveiler D, Amouyel P, Ferrieres J, Ducimetiere P, Patterson CC, Luc G (2008) Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis 197(2):556-563
104. Tsuchida S, Satoh M, Umemura H, Sogawa K, Kawashima Y, Kado S, Sawai S, Nishimura M, Kodera Y, Matsushita K, Nomura F (2012) Proteomic analysis of gingival crevicular fluid for discovery of novel periodontal disease markers. Proteomics 12(13):2190-2202
105. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM (2002) Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106(4):484-490
106. Underhill DM, Ozinsky A (2002) Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 14(1):103-110
107. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, Pays A, Tebabi P, Van Xong H, Jacquet A, Moguilevsky N, Dieu M, Kane JP, De Baetselier P, Brasseur R, Pays E (2003) Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422(6927):83-87
108. Vanhollebeke B, De Muylder G, Nielsen MJ, Pays A, Tebabi P, Dieu M, Raes M, Moestrup SK, Pays E (2008) A haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in humans. Science 320(5876):677-681
109. Vila A, Korytowski W, Girotti AW (2002) Spontaneous transfer of phospholipid and cholesterol hydroperoxides between cell membranes and low-density lipoprotein: assessment of reaction kinetics and prooxidant effects. Biochemistry 41(46):13705-13716
110. Vishnyakova TG, Kurlander R, Bocharov AV, Baranova IN, Chen Z, Abu-Asab MS, Tsokos M, Malide D, Basso F, Remaley A, Csako G, Eggerman TL, Patterson AP (2006) CLA-1 and its splicing variant CLA-2 mediate bacterial adhesion and cytosolic bacterial invasion in mammalian cells. Proc Natl Acad Sci U S A 103(45):16888-16893
111. Voisset C, Op de Beeck A, Horellou P, Dreux M, Gustot T, Duverlie G, Cosset FL, Vu-Dac N, Dubuisson J (2006) High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol 87(Pt 9):2577-2581
112. Webb NR, Connell PM, Graf GA, Smart EJ, de Villiers WJ, de Beer FC, van der Westhuyzen DR (1998) SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells. J Biol Chem 273 (24):15241-15248
113. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363(9410):689-695
114. Williams KJ, Tabas I (1995) The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15(5):551-561
115. Yan YJ, Li Y, Lou B, Wu MP (2006) Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci 79(2):210-215
116. Yoshikawa M, Sakuma N, Hibino T, Sato T, Fujinami T (1997) HDL3 exerts more powerful antioxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Clin Biochem 30(3):221-225
117. Zerrad-Saadi A, Therond P, Chantepie S, Couturier M, Rye KA, Chapman MJ, Kontush A (2009) HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 29(12):2169-2175
118. Zhang X, Zhu X, Chen B (2010) Inhibition of collar-induced carotid atherosclerosis by recombinant apoA-I cysteine mutants in apoE-deficient mice. J Lipid Res 51(12):3434-3442